“Grayson invested before the data release,” she continued. “Huge position. Then he joined NovaLife’s strategic advisory board six months later. And look at this—Sterling Weston Children’s Center was the primary trial site.”
Sterling Weston.
Grayson’s philanthropic crown jewel.
The wing he named after donating five million dollars.
The hospital where Sarah died.
“He controlled the site,” I whispered.
“Influenced, at minimum.” Lena leaned closer. “If the trial data is fabricated, NovaLife collapses. If NovaLife collapses, Athena gets margin-called into oblivion.”
“That sounds like a start.”
“It sounds like financial war.”
Sam found the second crack.
Catherine’s Vestri Gallery.
On paper, it sold modern and historical art to private collectors. In reality, Sam’s long-lens photos showed crates entering a Chelsea warehouse with suspicious manifests: pre-Columbian gold masks, Eastern European icons, ceramics from war zones, items with provenance too vague to survive daylight.
Michael traced shell companies.
Muse Holdings.
Cayman Islands.
Money moving through Cyprus banks, then into Catherine’s acquisitions at inflated values.
The art was used as collateral for loans.
The lender?
Grayson’s fund.
Lena mapped it on the wall: stolen art, inflated appraisals, laundering, fund performance, hospital contracts, biotech investments.
“It’s a fraud loop,” she said. “Athena loans money to shell buyers tied to Catherine. The gallery sells stolen or misrepresented art. That collateral supports more loans, more inflows, more fake value. Meanwhile, Grayson uses hospital relationships to steer contracts toward companies he owns or funds.”
The center was children’s cancer.
The engine was suffering.
I went numb.
Not because I did not understand.
Because I did.
My daughter had not merely been a patient in the wrong system.
She had been placed at the center of a machine built to turn hope into money.
I entered that machine publicly through art.
Margot Lane, a fierce art critic from my RISD days, opened the door.
I sent her one photo:
Study in Gray No. 1.
The painting was made with gesso, oil, wax, charcoal, and a small measure of Sarah’s ashes. I had mixed the gray powder with my bare hands until grief became texture.
Margot replied in eleven minutes.
My God, Philippa. Come Thursday.
Her apartment smelled of cigarettes, whiskey, and wet wool.
She stared at the image on her laptop.
“This is not pretty,” she said.
“No.”
“It’s devastating.”
“It should be shown.”
My throat tightened.
“I used her ashes.”
Margot did not flinch.
“Then it cost you something. Good art should.”
The show became
Cold Ash.
A small, brutal solo exhibition at Margot’s project space.
The paintings were not portraits of Sarah. I could not bear that. They were maps of grief: a small handprint dissolving into gray, a window with a yellow bird outside, a vortex of ash and silver leaf, and one painting called
The Serpent’s Bargain
, built from Sarah’s last drawing—the two snakes as buttons on a red dress.
The art world came because it smelled tragedy.
Then stayed because the work would not let them look away.
Catherine came with Grayson on opening night.
Of course she did.
She wore ice-blue silk and a smile sharpened at both ends.
Grayson stood beside her, polished, powerful, angry beneath the jawline because he recognized the snakes.
“Philippa,” he said quietly. “This is unexpected.”
“It’s an opening,” I said. “People come in.”
Catherine looked at the paintings with theatrical pity.
“How raw,” she murmured. “Almost too literal, don’t you think? But I suppose grief needs somewhere to go.”
The nearby guests leaned closer.
I smiled.
“You’re right, Catherine. Grief does need somewhere to go. So does stolen provenance.”
Her smile tightened.
“Excuse me?”
“I’ve been studying ceramics,” I said softly. “That Ming vase at your gallery? The glaze was wrong. Beautiful reproduction, though. I hope the insurance claim was worth the premium.”
For the first time, fear moved behind her eyes.
A flicker only.
Enough.
I stepped closer, lowering my voice so only she and Grayson could hear.
“How is the secondary market for pre-Columbian gold these days?”
Grayson’s face hardened.
“You’re unwell.”
“No,” I said. “I’m awake.”
The next morning, Lena called.
“I found Dr. Aerys Thorne,” she said. “Primary investigator on the Celestea trial at Sterling Weston. He left NovaLife six months ago with a payout and a gag order. Now he’s working at a free clinic in the Bronx.”
“Set a meeting.”
“He might not talk.”
“Then we make the silence expensive.”
But someone reached him first.
A black SUV appeared outside his clinic. He canceled. Then vanished from his apartment for three days.
That was when NovaLife received unexpected breakthrough therapy designation from the FDA for a secondary indication.
The stock exploded upward.
Our short position bled red.
Nemesis Capital, the tiny fund Lena and I had built from my settlement money and a few cynical investors, was now losing tens of millions on paper.
Grayson went on CNBC that morning.
I watched him from the war room as he spoke with that grave, practiced expression investors mistook for integrity.
“My daughter lost her battle,” he said, “but her spirit is in every vial of Celestea.”
Lena muted the television before I could throw something.
“He’s selling,” she said, eyes on the order flow. “Huge blocks. He’s using the FDA news to dump part of Athena’s position.”
“He knew before the announcement.”
“Almost certainly.”
“He’s cashing out on Sarah again.”
Lena did not answer.
She did not need to.
We were nearly wiped out that day.
I called my father.
“Dad, I need ten million.”
The line crackled with Gulf rig noise.
“A loan?”
“Against your mother’s trust.”
I closed my eyes.
My mother’s trust.
The last thing in my life untouched by Grayson.
“You’d be betting it all on breaking him,” my father said.
A long silence.
Then, “Your mother would hate that bastard.”
I laughed once, brokenly.
“She would.”
“She’d also tell you not to miss.”